51 research outputs found

    Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma

    Get PDF
    Purpose: Patients with primary cutaneous melanoma with a Breslow thickness greater than or equal to 1.5 mm have only a 30% to 70% probability of survival after surgery, and no adjuvant therapy has so far improved this outcome, Since interferon alfa-2a (IFN alpha 2a) exhibits antitumor activity in metastatic melanoma, we investigated whether adjuvant IFN alpha 2a diminishes the occurrence of metastases and thus prolongs disease-free survival in melanoma patients after excision of the primary tumor
    corecore